Michael Dickinson, Hematologist at Peter MacCallum Cancer Centre, shared on X:
“CAR T-cell therapy referral and uptake in relapsed/refractory large B-cell lymphoma: US claims analysis (Komodo Health, Oct 2016 to May 2025), 8959 adults after 2 or more prior lines.
It’s just a reality about market penetration in the USA: 20% were referred to an authorized treatment center and 15% received CAR-T. Referred patients were younger (median 61.5 vs 67.3 years, p<0.001) and lived closer to a center (median 17 vs 24 miles, p<0.001).”
Title: CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States
Authors: Mazyar Shadman, Loretta J. Nastoupil, Krish Patel, Manali Kamdar, Matthew A Lunning, Fei Fei Liu, Christine T. Fu, Michael Cantrell, Amit Goyal, Dwaipayan Mukherjee, Tara Graff.
You can also read: Sequencing CD19-Targeted Therapies in R/R LBCL: Key Concerns and Clinical Evidence
